Back to Search
Start Over
Infarcted myocardium-like stiffness contributes to endothelial progenitor lineage commitment of bone marrow mononuclear cells
- Source :
- Journal of Cellular and Molecular Medicine
- Publication Year :
- 2011
- Publisher :
- Wiley, 2011.
-
Abstract
- Optimal timing of cell therapy for myocardial infarction (MI) appears during 5 to 14 days after the infarction. However, the potential mechanism requires further investigation. This work aimed to verify the hypothesis that myocardial stiffness within a propitious time frame might provide a most beneficial physical condition for cell lineage specification in favour of cardiac repair. Serum vascular endothelial growth factor (VEGF) levels and myocardial stiffness of MI mice were consecutively detected. Isolated bone marrow mononuclear cells (BMMNCs) were injected into infarction zone at distinct time-points and cardiac function were measured 2 months after infarction. Polyacrylamide gel substrates with varied stiffness were used to mechanically mimic the infarcted myocardium. BMMNCs were plated on the flexible culture substrates under different concentrations of VEGF. Endothelial progenitor lineage commitment of BMMNCs was verified by immunofluorescent technique and flow cytometry. Our results demonstrated that the optimal timing in terms of improvement of cardiac function occurred during 7 to 14 days after MI, which was consistent with maximized capillary density at this time domains, but not with peak VEGF concentration. Percentage of double-positive cells for DiI-labelled acetylated low-density lipoprotein uptake and fluorescein isothiocyanate (FITC)-UEA-1 (ulex europaeus agglutinin I lectin) binding had no significant differences among the tissue-like stiffness in high concentration VEGF. With the decrease of VEGF concentration, the benefit of 42 kPa stiffness, corresponding to infarcted myocardium at days 7 to 14, gradually occurred and peaked when it was removed from culture medium. Likewise, combined expressions of VEGFR2(+) , CD133(+) and CD45(-) remained the highest level on 42 kPa substrate in conditions of lower concentration VEGF. In conclusion, the optimal efficacy of BMMNCs therapy at 7 to 14 days after MI might result from non-VEGF dependent angiogenesis, and myocardial stiffness at this time domains was more suitable for endothelial progenitor lineage specification of BMMNCs. The results here highlight the need for greater attention to mechanical microenvironments in cell culture and cell therapy.
- Subjects :
- Male
Vascular Endothelial Growth Factor A
Cardiac function curve
Angiogenesis
Myocardial Infarction
elastic modulus
Neovascularization, Physiologic
Infarction
Bone Marrow Cells
Monocytes
Cell therapy
Andrology
Mice
chemistry.chemical_compound
Vascular Stiffness
Antigens, CD
Reaction Time
Animals
Humans
Medicine
AC133 Antigen
Femur
Fluorescein isothiocyanate
endothelial progenitor cells
Bone Marrow Transplantation
Glycoproteins
Mice, Inbred BALB C
business.industry
bone marrow-derived mononuclear cells
Endothelial Cells
Heart
Articles
differentiation
Cell Biology
medicine.disease
Lipoproteins, LDL
Vascular endothelial growth factor
Disease Models, Animal
Vascular endothelial growth factor A
medicine.anatomical_structure
chemistry
Immunology
Leukocyte Common Antigens
Molecular Medicine
Bone marrow
Peptides
business
Subjects
Details
- ISSN :
- 15821838
- Volume :
- 15
- Database :
- OpenAIRE
- Journal :
- Journal of Cellular and Molecular Medicine
- Accession number :
- edsair.doi.dedup.....e01275dc544adaec01a8c23bfc309cc8
- Full Text :
- https://doi.org/10.1111/j.1582-4934.2010.01217.x